Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | NOS2 | P35228 | 5/20 | 0.50 |
| ▸ | NOS1 | P29475 | 4/20 | 0.50 |
| ▸ | NOS3 | P29474 | 3/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | ARG1 | P05089 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3503365 | 1.00 | OTC (0.57) | OTCKDM4EMAPK1HIF1ANOS2 | |
| SCHEMBL2238055 | 1.00 | OTC (0.57) | OTCKDM4EMAPK1HIF1ANOS2 | |
| SCHEMBL236178 | 0.94 | KDM4E (0.56) | OTCKDM4EMAPK1HIF1ANOS2 | |
| SCHEMBL180969 | 0.94 | KDM4E (0.56) | OTCKDM4EMAPK1HIF1ANOS2 | |
| SCHEMBL919222 | 0.94 | KDM4E (0.56) | OTCKDM4EMAPK1HIF1ANOS2 | |
| Hydrochloric Acid SCHEMBL15669798 | 0.92 | KDM4E (0.54) | OTCKDM4EMAPK1HIF1ANOS2 | |
| SCHEMBL30125060 | 0.92 | KDM4E (0.59) | OTCKDM4EMAPK1HIF1ANOS2 | |
| Hydrochloric Acid SCHEMBL28854969 | 0.92 | KDM4E (0.54) | OTCKDM4EMAPK1HIF1ANOS2 | |
| Ethylene SCHEMBL28796155 | 0.91 | KDM4E (0.52) | OTCKDM4EMAPK1HIF1ANOS2 | |
| Lysine SCHEMBL20898428 | 0.88 | GSR (0.67) | OTCKDM4EMAPK1HIF1ANOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260009800-A1 | METHODS OF DIAGNOSIS AND GUIDING TREATMENT OF VULVOVAGINAL SYMPTOMS AND FEMALE SEXUAL DYSFUNCTION | UNIV ARIZONA (US) | 2026-01-08 | — | — | US | claimed |
| WO-2025100520-A1 | PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE | ペプチドリーム株式会社 | 2025-05-15 | — | — | WO | claimed |
| EP-4482852-A1 | PEPTIDIC INHIBITORS OF AMYLOID SELF- AND CROSS-ASSEMBLY | Technische Universität München (DE) | 2025-01-01 | — | — | EP | claimed |
| WO-2023161211-A1 | PEPTIDIC INHIBITORS OF AMYLOID SELF- AND CROSS-ASSEMBLY | Technische Universität München (DE) | 2023-08-31 | — | — | WO | claimed |
| EP-4230645-A1 | PEPTIDIC INHIBITORS OF AMYLOID SELF- AND CROSS-ASSEMBLY | Technische Universität München (DE) | 2023-08-23 | — | — | EP | claimed |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. | 2022-12-22 | — | — | US | claimed |
| CN-115279782-A | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases | 詹森生物科技公司 | 2022-11-01 | — | — | CN | claimed |
| WO-2022080385-A1 | PEPTIDE, AND MODIFICATION OF ANTIBODY WITH PEPTIDE | 国立大学法人京都大学 | 2022-04-21 | — | — | WO | claimed |
| EP-3805756-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| EP-3129909-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2017-02-15 | — | — | EP | claimed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| EP-2036918-A1 | PEPTIDE DERIVATIVE | Vexon, Inc. (JP) | 2009-03-18 | — | — | EP | claimed |
| US-20080009448-A1 | Peptide Derivative | VEXON, INC. (50%) (JP) | 2008-01-10 | — | — | US | claimed |
| EP-0749429-B1 | 3,5-DISUBSTITUTED AND 3,5,6-TRISUBSTITUTED 2-ISOXAZOLINES AND ISOXAZOLES, PROCESS FOR PREPARING THE SAME AND THEIR USE AS MEDICAMENTS | HOECHST AG (DE) | 1999-06-30 | — | — | EP | claimed |
| US-20260146106-A1 | BIFUNCTIONAL DEGRADERS OF GALACTOSE-DEFICIENT IMMUNOGLOBULINS | BIOHAVEN THERAPEUTICS LTD. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-3808347-B1 | SUBSTANCES FOR TREATMENT OF FATTY LIVER-RELATED CONDITIONS | SCANDIBIO THERAPEUTICS AB (SE) | 2026-05-20 | — | — | EP | disclosed |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | UNIV CALIFORNIA (US) | 2026-03-19 | — | — | US | disclosed |
| US-6121479-A | ANTIINFLAMMATORY AND ANTICARCINOGENIC AGENTS; AUTOIMMUNE DISEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-09-19 | — | — | US | disclosed |
| US-6060071-A | Ectoin and ectoin derivatives as moisturizers in cosmetics | MERCK PATENT GMBH (DE) | 2000-05-09 | — | — | US | disclosed |
| US-5814627-A | ANTIINFLAMMATORY AGENTS, ASTHMA; RHEUMATIC AND AUTOIMMUNE DISEASES; INHIBITORS OF LEUKOTRIENES, CYTOKINES, E.G. INTERLEUKINS, OXYGEN RADICALS AND PROTEASES | HOECHST AKTIENEGESELLSCHAFT (DE) | 1998-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | OTC 4590/4885KDM4E 4705/4885MAPK1 944/4885 |
| US-20260146106-A1 | BIFUNCTIONAL DEGRADERS OF GALACTOSE-DEFICIENT IMMUNOGLOBULINS | ASGR1, FCGR2A, FCGR3B | OTC 4646/4885KDM4E 3325/4885MAPK1 3168/4885 |
| US-20260009800-A1 | METHODS OF DIAGNOSIS AND GUIDING TREATMENT OF VULVOVAGINAL SYMPTOMS AND FEMALE SEXUAL DYSFUNCTION | SHBG, GNRHR, STIM2 | OTC 4651/4885KDM4E 3955/4885MAPK1 3656/4885 |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | IDO1, INMT, IDO2 | OTC 1197/4885KDM4E 553/4885MAPK1 3444/4885 |
| US-20080009448-A1 | Peptide Derivative | ARGLU1, NGLY1, NPR3 | OTC 4586/4885KDM4E 619/4885MAPK1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.